Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy

Published:2023-09 Issue: Volume:132 Page:107348
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Taylor Skyler,Murthy Guru Subramanian Guru,Runaas Lyndsey,Michaelis Laura C.,Carlson Karen,Atallah Ehab L.,Abedin Sameem M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference7 articles.

1. Advances in acute myeloid leukemia;Newell;BMJ,2021

2. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus dunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia;Lancet;J. Clin. Oncol.,2018

3. Single versus double induction with “7 + 3” containing 60 versus 90 mg daunorubicin for newly diagnosed AML: results form the randomized controlled SAL dauno-double trial;Rollig;Blood,2022

4. Anthracycline dose intensification in acute myeloid leukemia;Fernandez;N. Engl. J. Med.,2009

5. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group;Rowe;Cancer,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP